Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Vaccines Clinical Trials Infectious Diseases

Takeda Confident As Dengue Vaccine Shows Benefits Three Years Out

Protection Regardless Of Prior Infection

  • Analysis

Executive Summary

New long-term Phase III data for Takeda's candidate dengue vaccine show continued protection against illness and hospitalization, regardless of previous exposure, out to the three-year mark following the two-dose jab.

You may also be interested in...



Takeda Test Drives EMA’s Parallel Review Route For EU And Non-EU Markets

A new evaluation route that the European Medicines Agency launched last year came at the right time for Takeda’s dengue vaccine candidate. 

Positive Evidence Stacks Up For Takeda's Dengue Vaccine

New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of ASCO; Roche CEO on new opportunities; Sanofi sees success in MS; Phase II lupus win for AbbVie; and a Chinese product case study in psoriasis.

Table

View full table

Topics

Related Companies

Tags:
Vaccines Clinical Trials Infectious Diseases
Latest Headlines

Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space

Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier

Disc Sees Promise In Hematology With Former Roche Schizophrenia Candidate

Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data

See All
UsernamePublicRestriction

Register

SC144403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By